

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	inclisiran
Brand Name	Leqvio™
Dosage Form(s)	284 mg (inclisiran as inclisiran sodium) in 1.5 mL for subcutaneous injection
Manufacturer	Novartis Pharmaceuticals Canada Inc.
Submission Type	New Submission
Use Reviewed	Further lowering of low density lipoprotein cholesterol (LDL-C)
Common Drug Review (CDR)	Yes, the CDR recommended: Do Not Reimburse . Visit the CDR website for more details: www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Confidential%20Final%20CADTH%20Rec%20Final.pdf
Provincial Review	Inclisiran was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because the CDR recommended not to list inclisiran for further lowering of low density lipoprotein cholesterol (LDL-C).
Drug Coverage Decision	Non-Benefit
Date	September 27, 2022
Reasons	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none"> Inclisiran lowered LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH) or non-familial hypercholesterolemia (nFH) with atherosclerotic cardiovascular disease (ASCVD) who were already being treated with the highest possible dose of statins and in those who cannot tolerate treatment with statins. There is an identified need for treatments that can reduce LDL-C and cardiovascular morbidity and death; however, there is currently not enough evidence to show that inclisiran will reduce cardiovascular morbidity and death.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.